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Abstract
In this study we examined the potential inhibition by inter-
feron-y (IFN'y) of the early stages of low density lipoprotein
(LDL) oxidation mediated by human peripheral blood mononu-
clear cells (PBMC) and monocyte-derived macrophages
(NMDMN) in Ham's F-10 medium supplemented with physiologi-
cal amounts of L-tryptophan (Trp). We assessed LDL oxida-
tion by measuring the consumption ofLDL's major antioxidant
(i.e., a-tocopherol) and targets for oxidation (cholesteryllino-
leate and cholesterylarachidonate), together with the accumu-
lation of cholesterylester hydroperoxides and the increase in
relative electrophoretic mobility of the lipoprotein particle. Ex-
posure of PBMC orMDM to IFNy induced the degradation of
extracellular Trp with concomitant accumulation of kynuren-
ine, anthranilic and 3-hydroxyanthranilic acid (3HAA) in the
culture medium. Formation of3HAA, but neither Trp degrada-
tion nor formation ofkynurenine and anthranilic acid, was inhib-
ited by low amounts of diphenylene iodonium (DPI) in a con-
centration-dependent manner. In contrast to oxidative Trp me-
tabolism, exposure of human PBMC or MDM to IFN-y failed
to induce degradation ofarginine, and nitrite was not detected in
the cell supernatant, indicating that nitric oxide synthase was
not induced under these conditions. Incubation ofLDL in Trp-
supplemented F-10 medium resulted in a time-dependent oxi-
dation of the lipoprotein that was accelerated in the presence of
PBMC orMDM but inhibited strongly in the presence of both
cells and IFNy, i.e., when Trp degradation and formation of
3HAA were induced. In contrast, when IFNy was added to
PBMC or MDM in F-10 medium that was virtually devoid of
Trp, inhibition of cell-accelerated LDL oxidation was not ob-
served. Exogenous 3HAA added to PBMC or purified mono-
cytes in the absence of IFNy also strongly and in a concentra-
tion-dependent manner inhibited LDL oxidation. Selective inhi-
bition of IFNy-induced formation of 3HAA by DPI caused
reversion of the inhibitory action of this cytokiine on both
PBMC- and MDM-mediated LDL oxidation. These results
show that IFN'y treatment of human PBMC or MDM in vitro
attenuates the extent of LDL oxidation caused by these cells,
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and indicate that Trp degradation with formation of3HAA is a
major contributing factor to this inhibitory activity. (J. Clin.
Invest. 1994. 93:2149-2158.) Key words: atherosclerosis * 3-
hydroxyanthranilic acid * indoleamine 2,3-dioxygenase * lipid
hydroperoxide * macrophages
Introduction
Oxidative modification of LDL may be important in the in
vivo formation oflipid-laden cells (i.e., foam cells) that signifi-
cantly contribute to the development of atherosclerosis ( 1, 2).
Although the precise molecular mechanism(s) underlying oxi-
dative LDL modification in vivo remains unknown, in vitro
studies on cell-mediated LDL oxidation are generally carried
out in medium containing small amounts of the transition
metals iron and/or copper. Under these conditions all cell
types present in a lesion (i.e., endothelial cells [3], macro-
phages [4], smooth muscle cells [5, 6] and lymphocytes [7])
are capable of oxidizing LDL. Where investigated directly, in
vitro cell-mediated LDL oxidation has been shown to have an
absolute requirement for the presence ofiron and copper in the
medium (3, 6); i.e., in their absence, these cells do not oxidize
LDL lipids substantially. The resulting modified LDL can be
taken up readily by macrophages, turning them into foam cells
similar to those observed in atherosclerotic lesions in vivo (8).
Antioxidants such as probucol (9), ascorbate (10), or ubi-
quinol-O0 ( 11), when added to these and other systems, sup-
press or completely inhibit LDL oxidation, indicated by the
decrease in the lipid hydroperoxides formed or the preserva-
tion of LDL-associated a-tocopherol (a-TOH) .'
Inhibition of murine macrophage-mediated LDL oxida-
tion has also been observed by treatment ofthe cells with inter-
feron-y (IFN'y) ( 12-14). IFNy-induced attenuation of cell-
mediated LDL oxidation correlated with induction of nitric
oxide radical (NO) synthesis from arginine ( 12, 14). In addi-
tion to NO formation, IFN-y can induce at least two other
pathways in mononuclear phagocytes that may attenuate LDL
oxidation: oxidative degradation ofheme and Trp initiated by
heme oxygenase and indoleamine 2,3-dioxygenase (IDO), re-
spectively. Both pathways eliminate potential pro-oxidants
while producing powerful antioxidants ( 15-19) (Scheme I).
We are interested in oxidative Trp degradation along the
kynurenine (Kyn) pathway and the concomitant formation of
1. Abbreviations used in this paper: CE-OOH, cholesterylester hydro-
peroxides; C1 8:2, cholesteryllinoleate; C20:4, cholesterylarachidonate;
DPI, diphenylene iodonium; 3HAA, 3-hydroxyanthranilic acid; IDO,
indoleamine 2,3-dioxygenase; Kyn, kynurenine; NO, nitric oxide radi-
cal; MDM, monocyte-derived macrophages; a-TOH, a-tocopherol;
Trp, L-tryptophan.
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Scheme I. Interferon-y-mediated induction in mononuclear phagocytes of pathways that may provide additional antioxidant protection. Me-
tabolites with reported antioxidant activity are underlined.
the antioxidant 3-hydroxyanthranilic acid (3HAA) because
this pathway is readily induced by IFNy in human (20, 21 )
monocytes/macrophages but not murine monocytes/macro-
phages (22) or human lymphocytes. In contrast, IFNy (to-
gether with LPS) readily inducesNO formation in murine mac-
rophages while at least in vitro this pathway is not induced in
human monocytes/macrophages by this and other cytokines.
Because a large proportion of lymphocytes present in athero-
sclerotic lesions appear to be activated, local release of IFNy
could result (23-25). We therefore examined whether IFNy
attenuated LDL oxidation mediated by human PBMC or
monocyte-derived macrophages (MDM) and, if so to what ex-
tent oxidative degradation of arginine and/or Trp contributed
to this activity. Oxidative modification ofLDL was assessed by
measuring the consumption of both a-TOH and polyunsatu-
rated esterified lipids, as well as formation of cholesterylester
hydroperoxides (CE-OOH) and changes in net surface charge
of the lipoprotein. Induction of IDO and NO synthase
(Scheme I) was determined by measuring Trp metabolites and
nitrite, respectively, in the cell culture supernatants. The results
obtained indicate that induction of IDO but not NO synthase
participates in the observed inhibition by IFNy of human
PBMC- or MDM-mediated LDL oxidation.
Methods
Materials. 3HAA, anthranilic acid, Kyn, EDTA, PBS, HBSS, (both
Ca2+- and Mg2+-free) and RPMI 1640 (powder) were obtained from
Sigma Chemical Co. (St. Louis, MO). L-Trp, chloroacetic and trichlo-
roacetic acid (TCA) were from Merck (Darmstadt, FRG), Ham's F-l0
medium (control No. 19K6422) from Gibco (Grand Island, NY), hu-
man recombinant IFN-y and chloramphenicol from Boehringer-
Mannheim GmbH (Mannheim, FRG), and potassium bromide from
British Drug House (BDH, Poole, England). Diphenylene iodonium
(DPI) was generously provided by Prof. O.T.G. Jones (University of
Bristol, UK) and given to us as a gift by Dr. W. Jessup (Heart Research
Institute); it was stored at -20°C as a 1 mM stock solution in 50%
ethanol (vol/vol). Tert-butyl alcohol and ethanol were from Rh6ne-
Poulenc (Paris, France) and BDH, respectively (both analytical grade),
and all other organic solvents (HPLC quality) from Mallinckrodt, Inc.
(Chesterfield, MO). LiquiPure water (MODULAB) was used for
buffers and aqueous solutions, which were subsequently treated with
Chelex-100 (Bio-Rad Laboratories, Richmond, CA) to remove con-
taminating transition metals. Buffers and media used for cell isolation,
elutriation and culture (except for F-10 media) were sterile-filtered
through Zetapor membranes (CUNO, Meriden, CT) and stored in
heat-treated (250°C for 3 h) glassware to minimize contamination
with endotoxin (LPS), tested for regularly using a chromogenic Limu-
lus amebocyte lysate test (26) (Associates of Cape Cod/American
Diagnostica, Greenwich, CT) and found to be < 50 pg/ml.
2150 Christen et al.
Heme
*-I Heme oxygenase
Co
41 Anthranilic acid
N'-Oxo-L-arginine
iNH2
I
Downloaded from http://www.jci.org on July 22, 2015.   http://dx.doi.org/10.1172/JCI117211
Preparation ofLDL. Human LDL (d 1.06 g/ml) was isolated
from anticoagulated (EDTA-K3 vacutainers, Becton Dickinson & Co.,
Mountain View, CA) plasma obtained from nonfasted, healthy, and
normolipidemic donors by rapid ultracentrifugation (2 h, 150C) (TL-
100.4 rotor in a TL-l00 benchtop centrifuge, Beckman Instruments,
Inc., Fullerton, CA) as described (27). The isolated LDL was then
dialyzed for 18 h against four changes of 100 vol of deoxygenated 10
mM PBS, pH 7.0, containing 0.1 mg/i chloramphenicol and 1 g/l
Chelex-100. Chelex was omitted in the last dialysis step. For some
experiments, the isolated LDL was gel-filtered (PD-bI column, Phar-
macia) rather than dialyzed. In all cases, the LDL was then filter steril-
ized (0.45 Am) and used immediately in experiments. LDL prepared in
this way consistently contained only low levels of cholesterylester hy-
droperoxides (CE-OOH), i.e., 45±38 pmol CE-OOH/mg LDL protein
(mean±SD, n = 10), corresponding to 1 CE-OOH molecule for
every 43 LDL particles. LDL protein concentration was determined
with BSA as the standard and using either the bicinchoninic acid
method (Sigma Chemical Co.) or the modified procedure of Peterson
(28) (Sigma Kit P 5656).
Isolation ofcells. Where feasible, PBMC were isolated from blood
obtained from the same donor used for the LDL preparation. Blood
was obtained under the guidelines and approval of the local human
ethics committee. For isolation oflarge numbers ofPBMC, monocytes
or MDM, white blood cell concentrates ("buffy coats," kindly pro-
vided by the N.S.W. Red Cross Blood Transfusion Service, Sydney)
were used. PBMC were isolated from diluted plasma or buffy coats by
centrifugation on Lymphoprep (NYCOMED, Oslo, Norway) and cul-
tured under nonadherent conditions (29) at 5 X 106 cells/ml in serum-
free Ham's F-10 medium containing either 10% (vol/vol) heat-inacti-
vated FCS (MultiSer, Cytosystems, Castle Hill, Australia) or 15% (vol/
vol) human AB serum (Red Cross).
Human monocytes (used at 1 X 106 cells/ml) and lymphocytes
were purified from PBMC (prepared from buffy coat) using counter-
flow centrifugal elutriation (30) carried out at 21 'C. The elutriation
system consisted of a Beckman JE-6 rotor in a Beckman J2-21M/E
centrifuge equipped with strobe assembly. Flow through the system
was controlled with a model 7545 Masterflex pump (Cole-Parmer In-
strument Co., Chicago, IL) equipped with a 7021-20 head. PBMC,
washed once with elutriation medium, were loaded into the elutriation
chamber in a final volume of 50 ml ( 1 X 109 cells) at a rotor speed of
2,020 rpm and an initial flow rate of 9.0 ml/min that was then in-
creased by 0.5 ml every 10 min. Platelets eluted immediately, followed
by lymphocytes (at a flow rate of 11.0 to 12.5 ml/min) and a mixed
lymphocyte/monocyte fraction (up to 15 ml/min), and finally puri-
fied monocytes (at 15.0 ml/min). After complete elution of this
mixed cell population, the flow rate was increased to 40 ml/min to
elute the remaining purified monocyte fraction. This procedure re-
sulted in lymphocyte (>99% purity) and monocyte preparations
(> 95% purity, as judged by nonspecific esterase staining, Sigma Kit
91 -A) of > 99% viability (trypan blue exclusion).
For MDM preparations, elutriated monocytes were washed and
resuspended in RPMI- 1640, and adhered for 90 min at 37°C in 22-mm
diam tissue culture wells (Costar, Cambridge, MA) at a concentration
of 1-3 X 106 cells/well. After adherence, the medium was replaced
with 1.5 ml RPMI-1640 with 10% (vol/vol) heat-inactivated human
serum, 20mM glutamine, 100 IU/ml penicillin and 100I g/ml strepto-
mycin, and the cells left to differentiate for 6 d at 37°C in 5% CO2 in air
with media changes on days 3 and 5. On day 6, MDM were > 99%
esterase positive and routinely yielded 200 sg protein/ 106 cells.
Oxidative modfication ofLDL. Ham's F- 10 medium was used for
all experiments; the medium contains 3 ,uM Trp and unless stated
otherwise, was supplemented with 75-100 AM L-Trp, a concentration
similar to that in human plasma, i.e., 60±15 AM (31). For PBMC and
purified monocytes experiment, LDL ( 2.5 mg protein/ml) (1 vol)
was incubated in Ham's F-10 medium (10 vol) for up to 24 h at 37°C
in a humidified atmosphere (5% CO2 in air) in the presence or absence
of cells. Aliquots (300 AI) of cell-free medium or cell suspension were
withdrawn at various times and, where needed, cells removed by cen-
trifugation (400 g for 10 min at 4VC). For MDM experiments, 0.6 ml
of LDL (100 Mg/ml F-10 medium) was added per well and incubated
for 24 h before the supernatant (600 Ml) was removed for lipid and
antioxidant analyses. Where indicated, human IFNY was added at
1,000 U/ml. In the case ofMDM, cells were preincubated for 20 h with
100 or 250 U/ml ofIFNy before addition ofLDL. The relative electro-
phoretic mobility of oxidized LDL ( 1-2 Mg) was determined using
precast agarose gels (Ciba-Coming, Palo Alto, CA) subjected to electro-
phoresis in barbitone buffer (pH 8.6) at 90 V for 45 min and stained
with Fat Red 7B stain (32). Before electrophoresis, the LDL contained
in the culture medium was concentrated by centrifuge-assisted ultrafil-
tration (Lida, Kenosha, WI).
Determination ofa-TOH, lipids, andCE-OOH byHPLC analysis.
Lipid-soluble antioxidants (including a-TOH), neutral lipids (mainly
free cholesterol and cholesterylesters) and CE-OOH were extracted
quantitatively from the LDL-containing cell culture supernatant as
described (10,27, 33, 34), and the extracts were stored at -70'C for up
to 24 h before analysis. Where indicated, cholesterylbenzoate was
added as an internal standard to the organic solvent before extraction
(27). In all other cases, lipid-soluble components of LDL were stan-
dardized internally against cholesterol. The hexane extracts were dried
under vacuum and redissolved in ethanol (180 ul) for analyses by
various HPLC methods. a-TOH and other lipid-soluble antioxidants,
including ubiquinol-1O, were determined by reversed-phase HPLC
with electrochemical detection (10). In some experiments, a-TOH was
determined in the lipid HPLC assay by fluorescence detection (292/
330 nm) (Spectra Physics, San Jose, CA; FL2000). Unoxidized neutral
lipids and CE-OOH were separated on an LC- 18 column (Supelco Inc.,
Bellefonte, PA; 25 X 0.46 cm with 5-cm guard column, 5-,um particle
size), eluted with tert-butyl alcohol/methanol (1: 1, vol/vol) at 1 ml/
min and detected by ultraviolet absorbance at 210 nm and post-co-
lumn chemiluminescence respectively, as described originally (33),
with the modification described (27).
Assessment ofTrp and arginine metabolism. For Trp metabolism,
the culture medium (z 1 ml) was deproteinized with TCA (4% final
concentration, wt/vol) after cells had been removed by centrifugation.
Trp, Kyn, and anthranilic acid in the resulting supernatant were sepa-
rated on a VeloSep RP-18 column (Applied Biosystems, Inc., Foster
City, CA; 10 x 0.32 cm with i-cm guard column, 3-,um particle size)
with 100 mM choloroacetic acid/acetonitrile (pH 2.2) (8:2, vol/vol)
and detected photometrically (Kyn, 365 nm; Trp, 280 nm) or fluori-
metrically (anthranilic acid, 328/422 nm) (35). 3HAA was deter-
mined by electrochemical detection (+0.5 V), either on-~line with the
above HPLC system (using an LKB/Pharmacia model 2143 detector
with glassy carbon electrode) or after extraction into ethyl acetate and
separation on an LC-18-DB column (Supelco, 25 X 0.46 cm with
guard column, 5-Mm particle size) (29). Degradation of arginine was
assessed by measuring the nitrite present in the supernatant of the
LDL-modifying cell cultures using the Griess reagent (36); and/or by
HPLC amino acid analysis using the o-phthalaldehyde method (37).
Statistical data analysis. The paired Student t test (one-tailed) was
used to evaluate differences in the absolute values ofthe various groups
of treatments. Significance was accepted at the P < 0.05 level, unless
stated otherwise. Owing to the relatively large variations in antioxidant
and lipid content of LDL preparations from different donors (38),
a-TOH, and cholesterylesters containing polyunsaturated fatty acids,
i.e., cholesteryllinoleate (C 18:2) and cholesterylarachidonate (C20:4),
were expressed as percent values relative to the initial concentration
and presented as mean±SD or SE, and range. CE-OOH values were
given in absolute concentrations.
Results
As has been reported by others (20, 39), incubation ofPBMC
or MDM in RPMI 1640 + 10% FCS and in the presence of
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IFNy resulted in induction ofIDO as assessed by the time-de-
pendent decrease of Trp and concomitant accumulation of
Kyn, anthranilic acid, and 3HAA in the culture medium (not
shown). In the absence of IFNy, degradation of Trp and for-
mation of Kyn pathway metabolites were much smaller, and
exposure of purified lymphocytes to IFNy in the absence of
monocytes did not result in significant Trp degradation (not
shown). These results demonstrate that IFNy induces Trp deg-
radation in human monocytes/macrophages but not lympho-
cytes. Furthermore, the presence of lymphocytes does not af-
fect the extent ofIFNy-induced Trp degradation by monocytes
(not shown, 39).
Studies on "cell-mediated" oxidative LDL modification
are mostly carried out in serum-free Ham's F-l0 (e.g., 3, 6), a
medium that contains added transition metals. Where investi-
gated directly, the transition metals have been demonstrated to
be required for the oxidation process to proceed (3, 6). In stud-
ies using transition metal-poor RPMI 1640 medium, Cathcart
and co-workers have shown that activated but not unactivated
monocytes oxidize LDL as assessed by the comparatively less
specific (to the methods used here) thiobarbituric acid reactive
substances assay (e.g., 4, 40). To study a potential effect ofTrp
metabolism along the Kyn pathway on monocyte/macro-
phage-mediated LDL oxidation, we therefore initially exam-
ined the efficacy with which IFNy induces oxidative Trp metab-
olism in PBMC cultured in Ham's F- 10, a medium permissive
for cell-mediated LDL oxidation. Table I shows that IFNy also
induced Trp degradation and metabolite formation in F-10
medium, with 3HAA and Kyn plus anthranilic acid account-
ing for 2 and 63% of the Trp lost, respectively. Although
detected, 3-hydroxykynurenine, a precursor of 3HAA, did not
accumulate to concentrations > 0.2 ,tM (not shown). It has
been reported recently (41 ) that quinolinic acid (which we did
not measure and which does not contain antioxidant moieties)
accounts for a significant proportion of the additional Trp de-
graded by human MDM; (see, however, reference 20). Addi-
tion ofLDL to PBMC cultured in F- 10 did not affect the extent
of IFNy-induced Trp degradation and metabolite formation
(Table I). Cell viability (measured by trypan blue exclusion) in
the (serum-free) F-10 medium was 2 95% after 24 h ofincuba-
tion and therefore did not affect our experiments on LDL oxi-
dation (see below) which were carried out with cells cultured
for up to 24 h only.
Incubation ofPBMC or MDM in F-10 medium in the ab-
sence or presence of IFNy for 24 h did not result in detectable
formation (2 0.5 nmol) of extracellular nitrite (not shown).
Treatment of these cells with IFN-y also did not result in a
decrease in extracellular arginine, as assessed by amino acid
analysis ofthe cell supernatant (not shown). These results indi-
cate that the nitric oxide pathway was not induced under our
conditions, consistent with data reported by others for human
MDM (42), but in contrast to the situation observed with mu-
rine macrophages (see reference 12 and references cited
therein).
Table II summarizes the results obtained for LDL oxida-
tion in F-10 medium in the absence or presence of human
PBMC or purified monocytes, and the effects of added IFNy
(z I03 U/ml) or 3HAA (10 ,M) on it. LDL oxidation was
assessed by three different methods: the loss ofa-TOH, quanti-
tatively the major lipid-soluble antioxidant associated with
LDL (38); the accumulation of CE-OOH, the major initial
lipid oxidation product formed in oxidizing LDL (10, 34, 43);
and the increase in LDL's relative electrophoretic mobility, an
index ofthe surface charge ofthe LDL particle. As can be seen,
incubation of LDL in Ham's F-10 medium for 24 h in the
absence ofcells resulted in oxidation ofthe lipoprotein, as indi-
cated by alteration of all three oxidation parameters. Signifi-
cant LDL lipid peroxidation was observed in the presence of
a-TOH; in fact, on average some 36 molecules of CE-OOH
were formed for each molecule of a-TOH consumed (Table
II). Since the rates ofa-TOH consumption and CE-OOH for-
mation are indicative for the rates ofinitiation and propagation
of lipid peroxidation in LDL respectively, these results demon-
strate that cell-free LDL peroxidation in F-10 medium pro-
ceeded via a chain reaction, despite the presence of a-TOH.
This is consistent with recent findings (44, 45) that indicated
that under these conditions LDL lipid peroxidation is actually
mediated by a-TOH. Cell-free LDL peroxidation was inhibited
almost completely by the addition of 10 MM 3HAA.
Incubation ofLDL in the presence ofeither PBMC or puri-
fied monocytes markedly accelerated lipoprotein oxidation, as
indicated by a greater loss of a-TOH and extent of CE-OOH
accumulation as well as increase in relative electrophoretic mo-
bility (Table II). As was the case in the cell-free system, LDL
lipid peroxidation occurred despite the presence of significant
levels of a-TOH. On a molar basis, relatively more CE-OOH
were detected than a-TOH lost. The simplest explanation for
this is that cell-mediated LDL lipid peroxidation also pro-
ceeded via a chain reaction. Co-incubation of PBMC with
IFNy significantly decreased the extent ofLDL oxidation (Ta-
Table L Effects ofIFNy on Extracellular Levels of Trp and Kyn Pathway Metabolites Produced by Human PBMC Incubated
in F-O0 Medium in the Absence (-) or Presence (+) ofLDL for 24 h at 370C
Metabolite* Trp Kyn AA 3HAA
LDLV - + - + - + - +
Cell-free (,gM) 95.8±5.7 102.5±7.3 0.28±0.4 0.40±0.3 ND ND <0.01 0.02±0.04
PBMC (nmo1 105.9±13.2 104.1±10.2 0.69±0.5 0.56±0.3 ND ND 0.07±0.1 0.03±0.04
PBMC/rIFN-y (_103 U/ml) 56.4±12.9 56.3±7.0 30.7±3.8 29.7±8.0 1.44±0.5 1.52±0.8 0.96±0.4 0.75±0.4
* Values represent concentration in micromolar (cell-free) or nanomoles per 5 X 106 cells presented as mean±SD of three to seven independent
experiments performed in duplicates or single determinations. $ Dialyzed.
ND, not detectable.
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Table II. a-TOH and CE-OOH Levels, and Relative Electrophoretic Mobility ofLDL after Incubation in Ham's F-JOfor 24 h
in the Absence or Presence ofPBMC or Purified Monocytes*
LDL only LDL + PBMC LDL + monocytes
Control No addition +3HAAt No addition rIFN-y +3HAA* No addition +3HAAt
F-10 (6) (6) (4) (5) (4) (3) (2) (2)
a-TOH (%)§ 100a 82.1±17.7b 87.7±17.88.c 16.6±23.8d 46.2+34.6bc 87.6±8.7ac 41.7 88.4
CE-OOH (gM)11 0.12±0.21a 12.7±10.7b 0.05±0.04ab 28.0±10.3c 14.6+15.4 ab o.oo+o.oab 41.6 0.09
Relative electrophoretic
mobility 1.008 1.24+0.18 1.08±0.17a- (5) 1.47±0.18c 1.24±0.20b 1.14±0.13a 1.44 (1) 1.11 (1)
Results are expressed as means±SD (numbers in parentheses represent number of independent experiments). Values within rows sharing the
same letter(s) are not significantly different from each other.
* Cells (5 X 106 PBMC/ml or 106 monocytes/ml) preincubated in RPMI 1640 + 15% human serum for 2-3 h at 370C before 24-h exposure to
LDL with and without additives. * Final concentration was 10 MM (includes data from experiments in F-10 medium without added Trp).
§ Initial concentration (= 100%) was 1.95±0.84 MM (mean±SD) ranging from 0.9 to 2.91 ,uM. 1' CE-OOH of control LDL was determined after
sterile-filtration prior to the incubation. The level ofCE-OOH of the freshly prepared LDL before gel-filtration and any further treatment was
0.007±0.01 MM (mean±SD, n = 6), consistent with the very low concentrations found in rapidly isolated LDL (10, 34).
ble II). An even greater effect was observed, when the potent
antioxidant 3HAA ( 17) was added to the cells at the beginning
of the incubation and in the absence of IFNy. In this case,
concentrations ofCE-OOH and a-TOH as well as LDL's rela-
tive electrophoretic mobility were indistinguishable from the
corresponding control values. Monocyte-mediated oxidative
modification of LDL was prevented similarly by the addition
of 3HAA (Table II). These results demonstrate that LDL
(per)oxidation in F-10 medium proceeds via a chain reaction
that is accelerated by human mononuclear cells, but can be
inhibited strongly by either addition ofmicromolar amounts of
3HAA or treatment of the cells with IFNy.
Since the concentrations of 3HAA used in Table II ex-
ceeded those formed by PBMC activated by IFNy (cf. Table I)
we examined the concentration-dependent inhibition ofLDL
oxidation by 3HAA. As can be seen in Fig. 1, 3HAA inhibited
LDL oxidation at very low concentrations, in the presence or
absence of cells. In both cases, accumulation ofCE-OGH was
strongly inhibited by 3HAA concentrations as low as 0.5 ,M,
where only 10-20% of the extracellular a-TOH was lost.
Addition of Kyn (50 MM) together with AA (2 MM) to the
cell-free or PBMC-containing system at concentrations similar
to those produced by IFNy-treated cells after 24 h (cf. Table I)
did not reduce LDL oxidation significantly (data not shown).
Similarly, added ascorbic acid (0.5 MM) did not significantly
inhibit PBMC accelerated LDL oxidation (not shown). These
results show that 3HAA at a concentration similar to that pro-
duced by IFNy-treated PBMC strongly inhibits LDL lipid per-
oxidation.
One approach to assess the extent ofparticipation ofoxida-
tive Trp degradation in the observed IFNy-induced inhibition
of PBMC-mediated LDL oxidation in general and that of
3HAA in particular, would be to selectively inhibit 3HAA for-
mation in stimulated mononuclear cells. The latter is depen-
dent on the monooxygenase-catalyzed hydroxylation of Kyn
(20) (Scheme I). Since monooxygenases are often flavin-de-
pendent enzymes, we tested whether the flavin analogue DPI
could inhibit 3HAA formation. Indeed, DPI inhibited IFNy-
induced formation of 3HAA by PBMC very effectively but
showed no significant effect on degradation ofTrp and forma-
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Figure 1. Inhibition ofLDL oxidation by 3HAA. LDL (dialyzed) was
incubated for 24 h at 37°C in F-10 medium only (o ), or in the pres-
ence ofPBMC (5 X 106 cells/ml, * ). Various amounts of3HAA were
added to the LDL-containing cultures at the beginning ofthe incuba-
tion. LDL oxidation was measured by determination ofextracellular
a-TOH and CE-OOH as described in Methods. Each value represents
the mean±SE of triplicate incubations ofa typical (of three cell-free
and two cell-containing) independent experiment. (A) a-TOH con-
centration remaining after 24 h ofincubation relative to that present
prior to incubation (i.e., 0.8 MM = 100%). (B) CE-OOH concentra-
tion, expressed relative to that detected after 24 h in the absence of
3HAA (i.e., 3.5 and 10.7 MM in the absence and presence of cells re-
spectively).
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tion of Kyn and anthranilic acid by these cells at concentra-
tions up to sM (Fig. 2). Comparable results were obtained
with MDM and whether LDL was present or not (not shown).
We next tested whether the inclusion ofDPI at a concentra-
tion that "selectively" inhibited 3HAA formation could re-
verse IFN-y-mediated inhibition ofPBMC-facilitated LDL oxi-
dation. The time-dependent analysis of such examination is
shown in Fig. 3. Incubation ofLDL in the presence ofPBMC
resulted in rapid consumption ofextracellular a-TOH after an
initial lag phase of 6 h (Fig. 3 A). This was paralleled by a
gradual loss from the medium ofC 18:2, the major polyunsatu-
rated core lipid and therefore substrate for oxidation in LDL
(Fig. 3 B). Concomitant with the decrease in a-TOH and
C1 8:2, extracellular CE-OOH increased (Fig. 3 C), accounting
for 82.7±43.6% (mean±SD, n = 4) ofthe C 18:2 lost. CE-OOH
represent those lipid hydroperoxides that are derived from poly-
unsaturated fatty acids in LDL esterified to cholesterol. How-
ever, since the cholesteryllinoleate hydroperoxide detected
during oxidation of human LDL usually accounts for more
than 85% of the total CEOOH formed (33) the above calcula-
tion (i.e., CE-OGH formed per C18:2 lost) gives a reasonably
accurate estimate of the degree of conversion of nonoxidized
core lipids into the corresponding hydroperoxides. Impor-
tantly, in the absence of IFNy, addition of DPI did not alter
cell-mediated LDL oxidation, as seen from the rates of a-
TOH/C18:2 consumption and CE-OOH formation (Fig. 3).
Likewise, LDL oxidation in F-l0 medium alone was not al-
tered by the addition ofDPI (not shown). In contrast, incuba-
tion ofLDL with PBMC in the presence ofIFNy prevented or
almost completely inhibited the consumption of C18:2 and
accumulation ofCE-OOH, and reduced the loss of a-TOH by
50% (Fig. 3). In some cases the amounts of CE-OOH de-
tected in the presence ofIFNy were similar to or even less than
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Figure 2. DPI-mediated "selective" inhibition of IFNy-induced for-
mation of 3HAA by PBMC. Cells (5 x 106/ml) were incubated in
the presence of IFN-'y (I03 U/ml) for 48 h at 37°C in the absence or
presence ofvarious concentrations ofDPI before supernatants were
analyzed for Trp (.), Kyn (A), AA (*) and 3HAA (v) as described
in Methods. Ethanol at the highest concentration used as solvent for
DPI (0.5%) had no significant effect on IFNy-induced Trp metabo-
lism. Values represent means±SD ofthree to seven independent ex-
periments and are expressed as percentage of the control incubation,
i.e., in the absence of DPI. The absolute control values (i.e., 100%
values) for Trp and its metabolites are indicated in Table I.
_- lUV
0
60
20
100
N
CO
,5
80
60~
24
0
9
LU
1 6
8
0
0 6 12 18 24 0 6 12 18 24
Time (h)
Figure 3. Time-dependent analysis of the inhibition of cell-mediated
LDL oxidation by IFNy and its partial reversal by DPI. LDL (dia-
lyzed) was incubated in the absence (o), or presence (solid symbols)
of untreated (A-C) or IFNy-treated ( 103 U/ml, D-F) PBMC (5
X 106 cells/ml, 2 ml final volume) at 37°C in the absence (o) or
presence (A&) of 20 nM DPI added at the beginning of the incubation.
Aliquots ofthe medium were analyzed for a-TOH (A and D), C 18:2
(B and E), and CE-OOH (C and F) using cholesterylbenzoate as the
internal standard as described in Methods. Initial concentrations
(means±SE) for a-TOH, C18:2, and CE-OOH were 1.25±0.3 (rang-
ing from 0.55 to 1.83), 95.6±19.0 (from 54.9 to 140.8), and
0.008±0.005 ALM, respectively. Each value represents the mean±SE
of4 independent experiments performed in duplicates. (Insets) CE-
OOH accumulation during cell-free (C) and IFNy-inhibited cell-me-
diated (F) LDL oxidation presented using an enlarged scale. *Signifi-
cantly different to corresponding value of untreated cells (minus
IFN-y). **Significantly different to IFNy-treated cells in the absence
of DPI.
those observed in the appropriate cell-free incubation (Fig. 3, E
and F insets). Addition of 20 nM DPI significantly reversed
part of the inhibitory effect of IFNy on consumption ofC 18:2
and accumulation of CE-OOH (Fig. 3, E and F). Since only
partial reversal was observed with this very low concentration
of DPI, we tested whether higher inhibitor concentrations
caused a more pronounced effects. Indeed, addition of 100 nM
DPI, a concentration that totally inhibited 3HAA formation
(Fig. 2), reversed the ability of IFNy to inhibit PBMC-me-
diated LDL oxidation between 51% and 100%, depending on
the parameter ofLDL oxidation measured (Table III).
As a second approach to assess whether Trp metabolism
along the Kyn pathway contributed to the observed inhibitory
action of IFNy on cell-mediated LDL oxidation, we used
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MDM in Ham's F- l0 medium that was not supplemented with
Trp. Commercial F-10 medium contains only low micromolar
concentrations of Trp, so that significant amounts of 3HAA
can not be formed by cells even when IDO is induced by treat-
ment with IFNy. Indeed, addition ofIFNy to MDM cultured
in nonsupplemented medium did not result in detectable Kyn
or 3HAA (data not shown) and had no effect on MDM-me-
diated LDL oxidation (Fig. 4). In contrast, IFNy treatment of
MDM in Tr-supplemented F-IO medium resulted in forma-
tion of micromolar amounts of 3HAA (ranging from 1 to 30
AM; depending on the cell numbers and IFNy dosage used)
and almost complete inhibition of LDL oxidation (Fig. 4).
Similar results were obtained with PBMC (not shown). Addi-
tion ofTrp (75 ,M) alone to either theMDM or cell-free incu-
bations only marginally affected LDL oxidation, whereas in-
clusion of DPI in the MDM/Trp/IFNy system caused sub-
stantial inhibition of Trp metabolism and reversion of the
cytokine's inhibitory effect on LDL oxidation (not shown).
Together, these results strongly support an important role of
3HAA formation in IFNy-mediated inhibition ofLDL oxida-
tion by human monocytes/macrophages.
Discussion
We have examined the potential inhibition by IFNy of the
early stages of human monocyte and macrophage-mediated
LDL oxidation in Ham's F- I0 medium containing physiologi-
cal amounts of added TmP, measuring the consumption of the
lipoprotein's major antioxidant (i.e., a-TOH) and targets for
oxidation (C 18:2 and C20:4) together with the accumulation
of CE-OOH, the primary and major oxidation product. Our
results show that as with murine macrophages, IFNy strongly
attenuates cell-mediated LDL oxidation by human mono-
cytes/macrophages. Unlike the murine system however, IFNy-
mediated inhibition ofLDL oxidation by human monocytes/
macrophages does not appear to be linked to NO biosynthesis,
as this pathway is not induced, at least under the experimental
conditions used in this study. In contrast, our results indicate a
Table III. Reversal ofthe Inhibitory Effect ofIFN-y
on PBMC-mediated Oxidation ofLDL by DPI
a-TOH* CE-OOHP CEPUFAS
% remaining AM % degraded
PBMC"1 0 29.5±2.8 79.5±2.8
PBMC + IFNy 20.7±4.4 5.7±2.5 10.8±10.0
PBMC + IFNy + DPI 0 18.0±2.5 67.0±5.0
F-l0 alone 5.0±5.1 13.5±5.8 39.8±3.5
DPI at 100 nM inhibited 3HAA formation by 100% consistent with
results shown in Fig. 2. 3HAA level in PBMC + IFN'y was 0.95
MM±0.2. Results are presented as means±SD of an individual experi-
ment carried out in triplicate and representative of 2 indpendent
experiments.
* Initial a-TOH concentration (100%) was 1.7 MM±0.3. * CE-OOH
level before addition to culture medium was 0.01 MM. f CEpuFu
refer to C 18:2 plus C20:4. 11 Cells (5 X 106 PBMC/ml) were incubated
in Ham's F-10, supplemented with 75 MM L-Trp, for 24 hr in the
presence ofLDL and the presence or absence of IFNy (1000 U/ml).
Figure 4. Inhibition of
100 A MDM-mediated LDL oxi-
dation by IFNy is depen-
a 80 dent on the presence of Trp
E2 60 in the culture medium.
RS T _ LDL (100 Mg protein/ml)
cNj 40 was incubated for 24 h in
u) 20 ~ _ _ Ham's FlO medium sup-
plemented (75 MM) or not
0 supplemented with Trp and
B in the absence and presence
1 2 ofMDM (3X 106cells/
well) and IFNy (1,000 U!
9 ml) before the concentra-
tions of cholesteryllinoleate
o (A),CE-OOH (B),and a-
TOH (C) in the medium
were determined (see
0 Methods). Before exposure
to LDL, MDM were pre-
cultured for 20 h in RPMI
- 80 1640 medium containing
_ 10% heat-inactivated hu-
60 man serum in the presence
or absence of IFNy (250
0 . U/ml). The results show
Zs020 the means±SD of triplicatedeterminations from one
0 out of three independent
MDM MDM MDM MDM experiments. In all three
Trp IFNy IFNy experiments IFNy-induced
Trp inhibition of MDM-me-
diated LDL oxidation was
dependent on Trp supplementation of the medium. In the absence
of IFNy addition of Trp to MDM had small but variable effects on
cholesteryllinoleate consumption and CE-OOH formation, but did
not affect a-TOH consumption. Initial concentrations (100% values)
of C18:2 and a-TOH are indicated in the legend to Fig. 3.
protective role for oxidative Trp metabolism and 3HAA for-
mation in this process.
The evidence for the participation ofoxidative Trp metabo-
lism and 3HAA formation in IFN'y-mediated inhibition ofhu-
man monocyte/macrophage-mediated LDL oxidation is based
on the following: Firstly, exposure of these cells to IFNy-
induced oxidative Trp metabolism along the Kyn pathway that
resulted in the release of low micromolar amounts of 3HAA.
Secondly, this aminophenolic metabolite is a powerful antioxi-
dant ( 17, 46): it strongly inhibited LDL oxidation when added
to both cell-free and cell-containing systems in the absence of
IFN'y and at concentrations similar to those formed by IFN-y-
treated mononuclear cells in vitro. Thirdly, incubation ofLDL
and IFNy with PBMC orMDM under conditions that resulted
in oxidative Trp degradation with concomitant formation of
3HAA, inhibited LDL oxidation to an extent similar to that
observed with exogenously added 3HAA. Fourthly, "selective"
inhibition of IFNy-induced formation of 3HAA by inclusion
of the flavoprotein inhibitor DPI (47, 48) reversed the inhibi-
tory action of this cytokine on mononuclear cell-facilitated
LDL oxidation. Finally, the inhibitory activity of IFNy on
MDM-mediated LDL oxidation was dependent on the pres-
ence of physiological amounts of Trp in the medium that did
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allow detectable levels of 3HAA to be formed. Together these
results show that 3HAA is a major contributing factor in the
IFNy-mediated inhibition of monocyte/macrophage-me-
diated LDL oxidation in transition metal containing medium.
Previous work by others has investigated a modulatory role
of IFNy on cell-mediated LDL oxidation. Cathcart et al. (49)
treated human monocyte-derived macrophages with this cyto-
kine to examine a possible contributory role of NADPH-oxi-
dase on LDL oxidation, but failed to detect an oxidation-en-
hancing effect. Hurt-Camejo and colleagues (50) showed
(though did not discuss) results consistent with an inhibitory
action of IFNy on LDL lipid oxidation mediated by human
MDM in RPMI 1640 medium supplemented with 5 1AM
CuS04 (their Table IV). This medium contains 25 ,gM Trp,
most of which would be expected to be degraded under their
conditions with formation of 3HAA (cf. Table I). This raises
the possibility that IDO-initiated Trp degradation too might
have contributed to the inhibition ofLDL oxidation observed
by these authors.
IFN'y is an important modulator of the immune response,
affecting many cellular functions of monocytes/macrophages
(51 ). Among these effects are an increased capacity of phago-
cytes to produce reactive oxygen species upon appropriate stim-
ulation and, conversely, the induction of Several metabolic
pathways that can be regarded as providing additional antioxi-
dant protection within and surrounding the cells (Scheme I).
Here we investigated induction of IDO, the initial and 02--
requiring enzyme (52) ofthe Kyn pathway that can give rise to
hydroxylated, antioxidant active metabolites ( 17) (Scheme I).
With one exception (i.e., A 498 kidney carcinoma cells), hu-
man monocytes/macrophages are the only cells known to pro-
duce and release 3HAA upon IFNy stimulation (20, 21). As
mentioned above, evidence forthe participation ofTrp metabo-
lism and 3HAA formation in particular, in the IFNy-mediated
inhibition of LDL (per)oxidation is based in part on the fact
that inclusion of submicromolar amounts of DPI reversed the
inhibition in consumption of a-TOH, C20:4 and C 18:2, and
formation of CE-OOH. The extent of this reversal increased
with increasing concentrations of DPI used (cf. Fig. 3 and Ta-
ble 4).
We have used DPI at low concentrations in an attempt to
inhibit formation of 3HAA without affecting other enzymatic
reactions that are known to be inhibited by higher concentra-
tions of DPI and may affect LDL oxidation. Thus, the final
concentration ofDPI used (20-100 nM) is some two orders of
magnitude lower than that required for inhibition ofNADPH
oxidase (53), the superoxide anion radical-producing enzyme
suggested to be involved in human PBMC-mediated LDL oxi-
dation (54). Also, inhibition ofNO synthase in murine macro-
phages requires somewhat higher DPI concentrations than
used in our experiments ( 12, 14, 48). In any case, an involve-
ment of this enzyme in the downregulation ofLDL oxidation
by IFNy as reported for mouse peritoneal macrophages ( 12,
13), is unlikely to be important in the human system, as nei-
ther accumulation of nitrite nor degradation of arginine from
the culture medium were observed. In contrast, our studies
using Trp poor medium clearly demonstrate a requirement for
Trp metabolism in the inhibitory activity seen by IFNy that is
affected by DPI.
Incubation of LDL in the presence of PBMC resulted in
detectable extracellular CE-OOH after an initial lag period of
6 h, when significant levels ofa-TOH were still present (Fig.
3). The observation that a-TOH was consumed during rather
than before the onset of lipid peroxidation is consistent with
our previous observations on cell-free, radical-mediated LDL
oxidation ( 10, 12, 44) and also transition metal-induced oxida-
tion (45). It is also consistent with a role for a-TOH-mediated
peroxidation (45) during PBMC-mediated LDL oxidation (in
the absence of suitable reductants for a-tocopheroxyl radical)
and LDL lipid peroxidation proceeding in a chain reaction. In
fact, preliminary studies showed that enrichment ofLDL with
a-TOH enhanced MDM-mediated lipid hydroperoxide forma-
tion during the early stages of lipoprotein oxidation in F-10
medium (Dr. Thomas, Dr. Jiri Neuzil, and Dr. Stocker, un-
published observations).
A striking finding of our study was the efficacy with which
very low concentrations of 3HAA inhibited LDL oxidation.
Although it is difficult to directly compare our results with
those from other groups, 3HAA is clearly one of the most effi-
cient LDL antioxidants known at present. Hence, an under-
standing of the mechanism(s) involved in this inhibition will
be important. 3HAA likely inhibited LDL oxidation at an early
stage of radical-induced chain oxidation of the lipoprotein,
whether cells were present or not. The possibility that 3HAA
chelates and makes the transition metals in Ham's F-10 me-
dium unavailable to participate in LDL oxidation, can be ruled
out for several reasons: Firstly, separate in vitro studies (Dr.
Christen and Dr. Stocker, unpublished observations) showed
that 3HAA (5 ,M) is unable to inhibit F- 10 medium-catalyzed
(aut)oxidation of ascorbate. Even when present at up to a 50-
fold molar excess over the metal, 3HAA does not inhibit Cu2+
or Fe3 -catalyzed oxidation of ascorbate in phosphate buffer,
pH 7.0. Secondly, neither the absorption nor fluorescence
spectra of 3HAA in solution are altered by the addition of
either Cu2+ or Fe3", suggesting that the aminophenol does not
complex with these metals under these conditions. This is con-
sistent with previous studies demonstrating that stable com-
plexes of 3HAA with Cu2+ or Fe3" are formed at alkaline pH
only, i.e., when both the amino and hydroxyl groups of3HAA
are deprotonated (the pK. values for amino and hydroxyl
groups are 5.2 and 10. 1, respectively) ( 55 ). Thirdly, the results
in Fig. 1 show that LDL oxidation is inhibited by concentra-
tions of 3HAA that are clearly below (i.e., submicromolar)
those of the transition metals present in Ham's F-10. (i.e., 3
,uM iron plus 0.01 tM copper).
Alternatively, 3HAA may protect LDL from oxidation by
reducing (or eliminating) the tocopheroxyl radical produced
from a-TOH, and/or maintaining (LDL-associated) ubi-
quinol-10 in the reduced, antioxidant active form. Either or
both of these reactions would provide powerful antioxidation
(10, 11, 44, 45). A reaction of tocopheroxyl radical with
aqueous reductants (antioxidants) has been reported for ascor-
bate and bilirubin (56, 57). While we are currently investigat-
ing these possibilities, it is clear from our results that if 3HAA
operates in one or both of the latter modes, components of
F-10 medium would have to maintain 3HAA in the reduced
state because it is not consumed substantially while providing
antioxidation. This opens the intriguing possibility that IFNy
modulates the production and/or release by monocytes/mac-
rophages of a "catalyst" for LDL antioxidation. Low concen-
trations of such a catalyst would be sufficient to provide sub-
stantial additional protection by maintaining LDL's antioxi-
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dant(s) in the reduced state through common and readily
available reductants which themselves are not efficient antioxi-
dants, and can not interact with LDL's a-TOH.
In addition to the protective antioxidant action of IFNy,
this cytokine is likely to have other effects relevant to atheroscle-
rosis. Thus, treatment ofhuman MDM with IFNy causes inhi-
bition of synthesis and secretion of lipoprotein lipase (58) as
well as expression of the scavenger receptor and the develop-
ment offoam cells in vitro (59). The suppressive effect ofIFNy
on production of platelet-derived growth factor by mononu-
clear phagocytes (60) may also be important in the control of
smooth muscle cell proliferation, which is a major event in the
development ofthe atherosclerotic plaque. It has been demon-
strated that IFNy administration regulates vascular smooth
muscle proliferation and inhibits lipase activity in vivo (61 ).
Lymphocytes and monocytes/macrophages are major cell
types present in the healthy intima at about the same ratio as in
circulation (25). As a fatty streak forms and progresses into a
lesion, the relative contribution ofmonocytes/macrophages in-
creases as does the absolute number ofcells (25). IFNy is likely
to be present in atherosclerotic lesions, as evidenced by the
presence ofMHC class II antigens and other specific activation
markers on cells found in those areas (23, 25). Induction of
IDO with release of3HAA thus appears feasible and may either
alone, or together with the aforementioned activities, influence
the development of atherosclerosis as well as other inflamma-
tory processes.
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